Suppr超能文献

5-氟尿嘧啶敏感和耐药的小鼠结肠腺癌中胸苷酸合成酶抑制的体内动力学

In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.

作者信息

Spears C P, Shahinian A H, Moran R G, Heidelberger C, Corbett T H

出版信息

Cancer Res. 1982 Feb;42(2):450-6.

PMID:6173112
Abstract

The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A. Thymidylate synthetase (TS) was determined by a tritiated 5-fluoro-2'-deoxyuridylate (FdUMP)-binding assay. Bolus 5-FUra (80 mg/kg, i.p.) administrated caused in all tumors a rapid decrease in free TS levels. Only Tumor 38, however, showed inhibition of TS to undetectable (less than 0.05 pmol/g) levels, which lasted up to 6 hr after treatment; correction for dissociation of endogenous TS: FdUMP:folate ternary complex during the TS assay was required. Total TS (free enzyme plus ternary complex) was determined with experimental conditions that achieved quantitative recovery of free TS from ternary complex. By 48 hr after 5-FUra, Tumor 38 showed a decrease in total TS proportional to the estimated log kill/dose of 5-FUra; in contrast, the resistant tumors showed no such decrease from pretreatment levels. Assay of FdUMP showed that the free nucleotide was formed rapidly in all tumors in excess over available TS-binding sites. However, tumor sensitivity did not correlate with peak or residual FdUMP levels or with deoxyuridylate levels, which were low and remained so in all tumors. Tumor sensitivity to 5-FUra also could not be explained by the small differences among the tumors in total perchloric acid-soluble metabolites of 5-FUra or drug incorporation into RNA. We conclude from these data that levels of free TS in the tumor after 5-FUra treatment are predictive of chemotherapeutic response in these murine models of human colonic adenocarcinoma.

摘要

在四种小鼠结肠腺癌中评估了5-氟尿嘧啶(5-FUra)作用的几个生化参数的预测效用:5-FUra敏感的肿瘤38以及5-FUra耐药的肿瘤07/A、51和06/A。通过氚标记的5-氟-2'-脱氧尿苷酸(FdUMP)结合试验测定胸苷酸合成酶(TS)。腹腔注射大剂量5-FUra(80mg/kg)导致所有肿瘤中游离TS水平迅速下降。然而,只有肿瘤38显示TS抑制至不可检测(低于0.05pmol/g)水平,该水平在治疗后持续长达6小时;在TS测定期间需要校正内源性TS:FdUMP:叶酸三元复合物的解离。在能够从三元复合物中定量回收游离TS的实验条件下测定总TS(游离酶加三元复合物)。5-FUra处理后48小时,肿瘤38显示总TS下降,与5-FUra估计的对数杀灭/剂量成比例;相比之下,耐药肿瘤与预处理水平相比没有这种下降。FdUMP测定表明,游离核苷酸在所有肿瘤中迅速形成,超过了可用的TS结合位点。然而,肿瘤敏感性与FdUMP的峰值或残留水平或脱氧尿苷酸水平无关,这些水平在所有肿瘤中都很低且一直如此。5-FUra对肿瘤的敏感性也不能用肿瘤之间5-FUra的总高氯酸可溶性代谢物或药物掺入RNA的微小差异来解释。从这些数据中我们得出结论,5-FUra治疗后肿瘤中游离TS的水平可预测这些人结肠腺癌小鼠模型中的化疗反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验